Novartis paused development of its CD19-directed autoimmune CAR-T program after three patient deaths following a dangerous immune response, according to reporting on trial safety. Bristol Myers Squibb also voluntarily paused related autoimmune CAR-T programs to review adverse-event signals. The halts come as both companies pursue immune reset strategies in autoimmune disease, where CAR-T dosing and patient-selection remain under intense scrutiny. The reports signal that safety issues in immune-cell reprogramming can quickly force protocol-level changes, potentially reshaping trial timelines and competitive positioning. Regulatory and sponsor follow-up will likely determine whether the programs return under modified inclusion criteria, monitoring, or product design.